Literature DB >> 20466673

Acute renal failure and Fanconi syndrome due to deferasirox.

Steven Grangé1, Dominique M Bertrand, Dominique Guerrot, Florence Eas, Michel Godin.   

Abstract

Deferasirox is the first oral iron chelator and, as such, is widely used for the treatment of chronic iron overload. However, recent data from large studies confirmed the renal toxicity of deferasirox. We report a case of Fanconi syndrome associated with acute renal failure in a patient receiving deferasirox. In particular, new insights regarding the pathophysiology of the renal disease due to this treatment are discussed. This case highlights the importance of a careful monitoring of kidney function, markers of proximal tubulopathy and ferritinaemia in patients receiving deferasirox.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20466673     DOI： 10.1093/ndt/gfq224

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  Deferasirox for managing iron overload in people with thalassaemia.

Authors:  Claudia Bollig; Lisa K Schell; Gerta Rücker; Roman Allert; Edith Motschall; Charlotte M Niemeyer; Dirk Bassler; Joerg J Meerpohl
Journal:  Cochrane Database Syst Rev       Date:  2017-08-15

2.  Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.

Authors:  Michel Baum
Journal:  J Pediatr Hematol Oncol       Date:  2010-10       Impact factor: 1.289

Review 3.  Deferasirox nephrotoxicity-the knowns and unknowns.

Authors:  Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz
Journal:  Nat Rev Nephrol       Date:  2014-07-22       Impact factor: 28.314

4.  Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.

Authors:  Laurence Dubourg; Céline Laurain; Bruno Ranchin; Corinne Pondarré; Aoumeur Hadj-Aïssa; Dominique Sigaudo-Roussel; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2012-04-24       Impact factor: 3.714

5.  Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study.

Authors:  Hamidreza Badeli; Adel Baghersalimi; Sajjad Eslami; Farshid Saadat; Afagh Hassanzadeh Rad; Rokhsar Basavand; Soghra Rafiei Papkiadeh; Bahram Darbandi; Wesam Kooti; Ilaria Peluso
Journal:  Oxid Med Cell Longev       Date:  2019-04-21       Impact factor: 6.543

6.  Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.

Authors:  Jacqueline Fraser; Rowena Brook; Tony He; Diana Lewis
Journal:  BMJ Case Rep       Date:  2020-07-09

Review 7.  Drug-Induced Metabolic Acidosis.

Authors:  Amy Quynh Trang Pham; Li Hao Richie Xu; Orson W Moe
Journal:  F1000Res       Date:  2015-12-16

8.  Acute kidney injury due to thin basement membrane disease mimicking Deferasirox nephrotoxicity: a case report.

Authors:  Keiko Oda; Kan Katayama; Akiko Tanoue; Tomohiro Murata; Yumi Hirota; Shoko Mizoguchi; Yosuke Hirabayashi; Takayasu Ito; Eiji Ishikawa; Kaoru Dohi; Masaaki Ito
Journal:  BMC Nephrol       Date:  2018-12-17       Impact factor: 2.388

9.  The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability.

Authors:  Esther M Gottwald; Claus D Schuh; Patrick Drücker; Dominik Haenni; Adam Pearson; Susan Ghazi; Milica Bugarski; Marcello Polesel; Michael Duss; Ehud M Landau; Andres Kaech; Urs Ziegler; Anne K M Lundby; Carsten Lundby; Petra S Dittrich; Andrew M Hall
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

10.  Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.

Authors:  Anthony Bentley; Samantha Gillard; Michael Spino; John Connelly; Fernando Tricta
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.